Montag & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.7M | Sell |
72,244
-2,746
| -4% | -$609K | 0.73% | 34 |
|
|
2025
Q4 | $17.1M | Sell |
74,990
-983
| -1% | -$224K | 0.78% | 30 |
|
|
2025
Q3 | $17.6M | Buy |
75,973
+197
| +0.3% | +$40.1K | 0.81% | 26 |
|
|
2025
Q2 | $14.1M | Sell |
75,776
-1,618
| -2% | -$301K | 0.69% | 37 |
|
|
2025
Q1 | $16.2M | Buy |
77,394
+5,302
| +7% | +$1.03M | 0.81% | 28 |
|
|
2024
Q4 | $12.8M | Sell |
72,092
-1,943
| -3% | -$357K | 0.61% | 44 |
|
|
2024
Q3 | $14.6M | Buy |
74,035
+2,770
| +4% | +$517K | 0.69% | 37 |
|
|
2024
Q2 | $12.2M | Sell |
71,265
-136
| -0.2% | -$22.5K | 0.62% | 45 |
|
|
2024
Q1 | $13M | Buy |
71,401
+3,690
| +5% | +$636K | 0.65% | 43 |
|
|
2023
Q4 | $10.5M | Sell |
67,711
-213
| -0.3% | -$31.1K | 0.59% | 47 |
|
|
2023
Q3 | $10.1M | Sell |
67,924
-61
| -0.1% | -$8.96K | 0.64% | 39 |
|
|
2023
Q2 | $9.16M | Buy |
67,985
+67
| +0.1% | +$9.82K | 0.56% | 43 |
|
|
2023
Q1 | $10.8M | Sell |
67,918
-665
| -1% | -$102K | 0.71% | 33 |
|
|
2022
Q4 | $11.1M | Buy |
68,583
+467
| +0.7% | +$71.6K | 0.74% | 33 |
|
|
2022
Q3 | $9.14M | Buy |
68,116
+2,780
| +4% | +$399K | 0.63% | 39 |
|
|
2022
Q2 | $10M | Sell |
65,336
-2,199
| -3% | -$336K | 0.65% | 34 |
|
|
2022
Q1 | $10.9M | Buy |
67,535
+110
| +0.2% | +$16K | 0.58% | 41 |
|
|
2021
Q4 | $9.13M | Sell |
67,425
-1,626
| -2% | -$192K | 0.45% | 58 |
|
|
2021
Q3 | $7.45M | Sell |
69,051
-700
| -1% | -$80K | 0.4% | 63 |
|
|
2021
Q2 | $7.86M | Hold |
69,751
| – | – | 0.42% | 65 |
|
|
2021
Q1 | $7.55M | Sell |
69,751
-1,832
| -3% | -$196K | 0.43% | 66 |
|
|
2020
Q4 | $7.67M | Buy |
71,583
+6,117
| +9% | +$588K | 0.47% | 62 |
|
|
2020
Q3 | $5.73M | Buy |
65,466
+1,262
| +2% | +$119K | 0.46% | 62 |
|
|
2020
Q2 | $6.3M | Buy |
64,204
+307
| +0.5% | +$27K | 0.55% | 50 |
|
|
2020
Q1 | $4.87M | Buy |
63,897
+920
| +1% | +$78.4K | 0.49% | 60 |
|
|
2019
Q4 | $5.58M | Sell |
62,977
-8,590
| -12% | -$713K | 0.45% | 61 |
|
|
2019
Q3 | $5.42M | Hold |
71,567
| – | – | 0.47% | 56 |
|
|
2019
Q2 | $5.2M | Buy |
71,567
+935
| +1% | +$73.5K | 0.46% | 57 |
|
|
2019
Q1 | $5.69M | Sell |
70,632
-200
| -0.3% | -$16.4K | 0.53% | 50 |
|
|
2018
Q4 | $6.53M | Buy |
70,832
+506
| +0.7% | +$44.5K | 0.7% | 40 |
|
|
2018
Q3 | $6.65M | Buy |
70,326
+635
| +0.9% | +$60.2K | 0.58% | 42 |
|
|
2018
Q2 | $6.46M | Sell |
69,691
-934
| -1% | -$91.2K | 0.66% | 38 |
|
|
2018
Q1 | $6.68M | Buy |
70,625
+1,026
| +1% | +$113K | 0.69% | 39 |
|
|
2017
Q4 | $6.73M | Sell |
69,599
-216
| -0.3% | -$20.4K | 0.65% | 42 |
|
|
2017
Q3 | $6.2M | Sell |
69,815
-534
| -0.8% | -$40.6K | 0.67% | 40 |
|
|
2017
Q2 | $5.1M | Buy |
70,349
+253
| +0.4% | +$17K | 0.57% | 50 |
|
|
2017
Q1 | $4.57M | Sell |
70,096
-495
| -0.7% | -$31.1K | 0.51% | 55 |
|
|
2016
Q4 | $4.42M | Hold |
70,591
| – | – | 0.52% | 58 |
|
|
2016
Q3 | $4.45M | Hold |
70,591
| – | – | 0.57% | 54 |
|
|
2016
Q2 | $4.37M | Sell |
70,591
-595
| -0.8% | -$36.3K | 0.58% | 55 |
|
|
2016
Q1 | $4.07M | Buy |
71,186
+445
| +0.6% | +$24.8K | 0.57% | 51 |
|
|
2015
Q4 | $4.19M | Buy |
70,741
+370
| +0.5% | +$21.3K | 0.61% | 51 |
|
|
2015
Q3 | $3.83M | Buy |
70,371
+330
| +0.5% | +$21.5K | 0.6% | 56 |
|
|
2015
Q2 | $4.71M | Sell |
70,041
-455
| -0.6% | -$29.7K | 0.69% | 48 |
|
|
2015
Q1 | $4.13M | Sell |
70,496
-700
| -1% | -$42.3K | 0.6% | 55 |
|
|
2014
Q4 | $4.66M | Buy |
71,196
+645
| +0.9% | +$40.7K | 0.7% | 43 |
|
|
2014
Q3 | $4.08M | Buy |
70,551
+4,306
| +7% | +$239K | 0.67% | 48 |
|
|
2014
Q2 | $3.74M | Buy |
66,245
+2
| +0% | +$105 | 0.61% | 54 |
|
|
2014
Q1 | $3.4M | Buy |
66,243
+4,329
| +7% | +$219K | 0.58% | 59 |
|
|
2013
Q4 | $3.27M | Buy |
61,914
+1,000
| +2% | +$49.1K | 0.56% | 59 |
|
|
2013
Q3 | $2.73M | Buy |
60,914
+171
| +0.3% | +$7.58K | 0.51% | 66 |
|
|
2013
Q2 | $2.51M | Buy |
+60,743
| New | +$2.66M | 0.51% | 66 |
|
Other funds holding ABBV
VCM
VPM
Montag & Associates's ABBV Position: Q1 2026 in Review
Montag & Associates reduced its AbbVie (ABBV) stake by 3.7% in Q1 2026, selling an estimated $609K and leaving 72,244 shares worth $15.7M. The position accounts for 0.73% of the portfolio, ranked #34.
Montag & Associates first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.6M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Montag & Associates held 72,244 shares of AbbVie worth $15.7M as of Q1 2026.
- Montag & Associates sold 2,746 AbbVie shares in Q1 2026, an estimated $609K.
- AbbVie made up 0.73% of Montag & Associates's portfolio in Q1 2026, its #34 holding.
- Montag & Associates first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Montag & Associates's AbbVie position peaked at $17.6M in Q3 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.